Clinical Takeaway Adolescents with higher levels of depression and anxiety symptoms show increased likelihood of initiating and using cannabis more frequently over time, supporting the self-medication hypothesis in this age group. This...
Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trial.
Medical cannabis is now commonly prescribed for a range of chronic health conditions. Many medical cannabis products contain delta-9-tetrahydrocannabinol (TH…
Adolescent Cannabis Use and Mental Health: Clinical Evidence
Clinical Takeaway Large-scale longitudinal data show that adolescent cannabis use is associated with increased risk of developing psychotic, bipolar, depressive, and anxiety disorders into young adulthood. These are clinically diagnosed conditions, not...
Endocannabinoid System Research: Cannabis Use After Trauma
Clinical Takeaway Insomnia symptoms present before a traumatic event may increase the risk of alcohol and cannabis use in the weeks and months following trauma exposure. Clinicians treating trauma survivors in emergency...
Cannabinoid Clinical Trials: Sleep & EEG Insomnia Study
Clinical Takeaway In this pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to...
`Cannabinoids for Mental & Substance Use Disorders: Evidence`
Clinical Takeaway Based on current randomized controlled trial evidence, the efficacy of cannabinoids for treating mental disorders and substance use disorders remains unestablished. Existing studies show limited and inconsistent benefits, and safety...
Cannabis Oil Did Not Meaningfully Reduce Pain in Nerve-Injury Patients, Rigorous Trial Finds
Our study findings indicate that cannabis-based medicine did not improve pain by a clinically important margin. Consequently, our study advises against the addition of cannabis-based medicine to the standard medication treatment for pain in patients with traumatic brachial plexus injury.
Australian Trial to Test Medicinal Cannabis Against Chemotherapy’s Gut Side Effects
“There are currently no effective approved interventions to prevent gastrointestinal symptom clusters in people undergoing cytotoxic cancer therapy.”
CBD Probably Reduces Seizures in Refractory Epilepsy, But Raises Risk of Serious Adverse Events
Cannabidiol 20 mg/kg/day and 10 mg/kg/day probably increased the frequency of participants who achieved a ≥50% reduction in monthly seizures (20 mg/kg/day: RR 1.92; 95% CI 1.49–2.46; 10 mg/kg/day: RR 1.94; 95% CI 1.32–2.86, moderate certainty). The incidence of serious adverse events is probably increased with CBD 20 mg/kg/day (RR 2.30; 95% CI 1.36–3.89, moderate certainty).
Expert Commentary Backs Negative Cannabis Trial for Brachial Plexus Pain
These negative results based on solid evidence will help surgeons to avoid raising false hopes and circumvent the use of futile therapies.